Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
The DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.
Abstract
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently become a major concern for a broad spectrum of health care providers. Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM) are at center stage, as T2DM appears to worsen the course of NAFLD and the liver disease makes diabetes management more challenging. However, the nature of this relationship remains incompletely understood. Although the increasing prevalence of NAFLD is frequently attributed to the epidemic of obesity and is often oversimplified as the "hepatic manifestation of the metabolic syndrome," it is a much more complex disease process that may also be observed in nonobese individuals and in patients without clinical manifestations of the metabolic syndrome. It carries both metabolic and liver-specific complications that make its approach unique among medical conditions. Diabetes appears to promote the development of nonalcoholic steatohepatitis (NASH), the more severe form of the disease, and increases the risk of cirrhosis and hepatocellular carcinoma. Patients and physicians face many uncertainties, including fragmented information on the natural history of the disease, challenges in the diagnosis of NASH, and few pharmacological agents with proven efficacy. However, recent advances in diagnosis and treatment, combined with the risk of serious consequences from inaction, call for health care providers to be more proactive in the managem…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NAFLD, and in particular NASH, is also associated with an increased risk of cardiovascular complications; therefore, people with NAFLD should have their cardiovascular risk factors assessed and managed to minimize this risk (303).”
In the citing paper
“Rat studies have shown that removal of visceral adipose tissue increases insulin sensitivity while delaying T2D (75), and prevents metabolic syndrome and NAFLD (76).”
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Research works printed but not linked: 1
- Sanyal, 2016, Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: results from the Year 1 primary analysis of the Phase 2b CENTAUR study (Abstract), Hepatology, 64, 1118A
Cited by
Items 301–341 of 341
Lazas, D. J., O'Rourke, J., Pontes, A., Aldous, M., Bachinski, M. S. Z., Barish, R. W., Brown, M., Din, R., Myers, M., Newman, F., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/01.ajg.0000706252.23999.cd
Журавльова, Л. В. (. )., Лахно, О. В., Tsivenko, O., & Кривоносова, О. М. (2021) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2021.2.01
Alhumaid, A. S., Tourkmani, A. M., & Kofi, M. A. (2021) · International Journal of Advanced Community Medicine · doi:10.33545/comed.2021.v4.i1a.181
NAFLD and its link with diabetes: Why we should be worried
Cremonesini, L., & Harkin, E. (2021) · Independent Nurse · doi:10.12968/indn.2021.8.20
Rezapour, S., Khosroshahi, S. A., Farajnia, H., Mohseni, F., Khoshbaten, M., & Farajnia, S. (2020) · doi:10.21203/rs.3.rs-39402/v3
Rezapour, S., Khosroshahi, S. A., Farajnia, H., Mohseni, F., Khoshbaten, M., & Farajnia, S. (2020) · doi:10.21203/rs.3.rs-39402/v1
Rezapour, S., Khosroshahi, S. A., Farajnia, H., Mohseni, F., Khoshbaten, M., & Farajnia, S. (2020) · doi:10.21203/rs.3.rs-39402/v2
Evaluation of Liver Changes in Type-2 Diabetes Mellitus Patients using Computed Tomography
Ashfaq, N., John, A., Ali, A. S., Bhatti, A. S., & Qaiser, H. (2022) · DIET FACTOR (Journal of Nutritional & Food Sciences) · doi:10.54393/df.v3i1.45
Hepatic Glycogenosis: A Modern Reality in Children with Type 1 Diabetes
Dassouli, C., Aboutarik, F., Errami, A. A., Oubaha, S., Samlani, Z., & Krati, K. (2022) · Scholars Journal of Medical Case Reports · doi:10.36347/sjmcr.2022.v10i11.012
Wazir, N., Rehman, S. U., Arshad, M., Wazir, M. Z., Khan, S., & Ullah, M. S. (2023) · Journal of Gandhara Medical and Dental Science · doi:10.37762/jgmds.10-2.375
Cuadrado, N. M. (2022) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/59897
Sánchez, C. N. T. (2022) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/59942
Tkach, S. M. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-3-62 · Cited by 1
Boreddy, V. R., Thopireddy, L., Kesireddy, S. R., & Saddala, R. R. (2023) · International Journal of Ayurvedic Medicine · doi:10.47552/ijam.v14i3.3962
Tratamiento farmacológico actual y futuro de la esteatosis hepática
Alonso, N., & Julián, M. T. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.esteatosis.art7
Miranda, G., & Herman Vildozola, G. (2023) · Revista de Gastroenterología del Perú · doi:10.47892/rgp.2023.434.1535
Association of TM6SF2 (E167K) with NAFLD in adult Greek people with Type 2 Diabetes Mellitus (T2DM)Preprint
Meritsi, A., Rapti, S., Latsou, D., Koussis, P., Zoumpoulis, P. S., & Thanopoulou, A. C. (2024) · Research Square · doi:10.21203/rs.3.rs-4118620/v1
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Self-citationGadallah, A.-N. A.-A., sheneb, A. A., Dala, A. G., Esawy, M. E.-H. E.-S., & Nooh, M. Z. (2024) · Surgery Gastroenterology and Oncology · doi:10.21614/sgo-642
Awan, S. A., Wibawa, I. D. N., Jawi, I. M., Pinatih, G. N. I., & Mahendra, A. N. (2023) · Bali Medical Journal · doi:10.15562/bmj.v12i2.4483
Diabetes Management with Current Guidelines.
Karadeniz, Y. (2023) · doi:10.69860/nobel.9786053359111.12
Integrative Approaches to MASLD Management
Dossaji, Z., Laeeq, T., Haque, L., Chun, M. J., & Gish, R. G. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_11
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.69 · Cited by 1
Self-citationMiranda, G., & Herman Vildozola, G. (2025) · Revista de Gastroenterología del Perú · doi:10.47892/rgp.2025.451.1847
曲, 云. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42249
Therapeutic Effects of Functional Food on Hepatic Disorders
Adhikary, K., Banerjee, A., Sadhu, D., Sarkar, R., Mohanty, S., & Karak, P. (2025) · Springer eBooks · doi:10.1007/978-981-96-8622-3_21
Guo, W., Lu, J., Qin, P., Li, X., Zhu, W., Wu, J., Xu, N., & Zhang, Q. (2020) · Figshare · doi:10.6084/m9.figshare.13064341
Park, J., Kim, G., Kim, B., Han, K.-D., Kwon, S. Y., Park, S. H., Lee, Y.-B., Jin, S.-M., & Kim, J. H. (2022) · Figshare · doi:10.6084/m9.figshare.19608174
Chung, G. E., Jeong, S.-M., Cho, E. J., Yoon, J. W., Yoo, J.-J., Cho, Y., Lee, K.-N., Shin, D. W., Kim, Y. J., Yoon, J.-H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26550982
Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
Damle, V. A., Sharma, A., Srivastava, B. K., Raveendran, A. V., Seshadri, K. G., & Mohan, V. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_85_25
Vicioso, M. P. F.-F., Vicente-Herrero, M. T., Gallegos, A. R., Ramírez‐Manent, J. I., López, P. T., del-Barrio, J. L., & López‐González, Á. A. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102671
Yang, R., Jiangfan, G., Wang, N., Qi, Z., Liu, C., Li, Q., Wu, L., Qin, L., & Liu, T. (2026) · Natural Product Communications · doi:10.1177/1934578x261420563
Abdou, H. A., & Omar, S. A. (2026) · ASIDE Gastroenterology · doi:10.71079/aside.gi.031826446
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63 · Cited by 1
Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
Smati, S. (2019) · theses.fr (ABES) · doi:10.70675/01997f55za990z41e6z96baz8221de2a6281
Li, B., Zhang, Y., Li, Z., Chen, Z., Guo, Z., Wu, W., Tan, L., Dong, L., Zhang, X., Lyu, X., et al. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04842-1
Impactos macroeconómicos del Covid-19 en El Salvador
Guevara, R. H. O. (2026) · Dimensión Empresarial · doi:10.15665/kpgxk075
Shetty, U. S. A., Batool, A.-E.-Z., Postoev, A., Abdul, R. H. M., Chaudhary, S., Jabeen, S., Wei, C. R., & Amin, A. (2026) · Cureus · doi:10.7759/cureus.109532
Shanka, N. Y., & Tadesse, T. T. (2026) · IgMin Research · doi:10.61927/igmin364
Lin, D., Lin, G., & Liu, Z. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1887682
Metadata
- Authors
- Bril, F., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Cusi, Kenneth
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-02-13
- Volume
- 40
- Issue
- 3
- Pages
- 419-430
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2589426226
- Cited by
- 341
- References
- 123
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 28 · 2023: 38 · 2022: 41 · 2021: 43 · 2020: 61 · 2019: 41 · 2018: 36 · 2017: 17
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, nonalcoholic steatohepatitis, metabolic syndrome, obesity, liver cirrhosis, hepatocellular carcinoma, NASH diagnosis, NASH treatment, disease natural history
- MeSH terms
- Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Humans, Hyperglycemia, Life Style, Liver Neoplasms, Obesity, Risk Factors, Prevalence, Randomized Controlled Trials as Topic, Metabolic Syndrome, Dyslipidemias, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.